Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232716 | 0.83 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL3118218 | 0.83 | MGAM (0.41) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL6825407 | 0.80 | GAA (0.45) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL7333520 | 0.79 | KDM4E (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL391332 | 0.76 | GAA (0.65) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL5650885 | 0.75 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL5650881 | 0.75 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28234269 | 0.74 | GAA (0.62) | GAAMGAMSIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27917473 | 0.74 | GAA (0.62) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL939170 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183253-B1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA SA (BE) | 2013-12-18 | — | — | EP | disclosed |
| US-8350037-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA, S.A. (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20100179124-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2010-07-15 | — | — | US | disclosed |
| EP-2183253-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB Pharma, S.A. (BE) | 2010-05-12 | — | — | EP | disclosed |
| EP-2170945-A1 | PROTEASE STABILIZED, PEGYLATED INSULIN ANALOGUES | Novo Nordisk A/S (DK) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009013462-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009010428-A1 | PROTEASE STABILIZED, PEGYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179124-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | GAA 4229/4885MGAM 3602/4885SI 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.